Truist analyst Jailendra Singh raised the firm’s price target on Agilon Health to $35 from $29 and keeps a Buy rating on the shares ahead of its Q1 results. The company should provide additional details around the performance of its health system partnership with MaineHealth and how that is progressing given the increasing importance of health systems in 2024, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AGL:
- Agilon’s 2024 revenue guidance of $5.5B likely conservative, says Guggenheim
- Final Medicare Advantage rates positive for managed care, says JPMorgan
- TD Cowen healthcare analyst to hold analyst/industry conference call
- Agilon Health to host investor day
- Holland PHO and Agilon Health form West Michigan partnership, no terms
